Good morning, everyone, and how are you today? We are doing just fine, thank you, despite persistently soggy and gloomy skies hovering over the Pharmalot campus. As the Morning Mayor used to say: “Every brand new day should be unwrapped like a precious gift.” So while you tug on the ribbon and ponder the possibilities, we will brew another cup of stimulation and proceed with our usual routine of foraging for interesting items. Speaking of which, here are a few tidbits to get you going. Have a smashing day and do keep in touch. …

A coalition of pharmaceutical industry critics is accusing the largest drug makers of hiding behind research and development “as an excuse for price-gouging American patients,” STAT writes. And they cite a new study that finds drug makers spent about 22% of their revenues on research and development in 2017 to prove their point. The study, commissioned by the Campaign for Sustainable Rx Pricing, was based largely on analysis of 2017 Security and Exchange Commission filings for the 10 largest U.S.-based drug makers that generate more than half their revenue from medicines.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • One wonders how much of the 340B increase is due to the increase in the base cost of the purchased product? That is an area that the article does not address, while it does seem to make a case that the absolute growth as opposed to the manufacturers net should be troubling.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy